Claims
- 1. An antibody that competitively inhibits binding of SLC15A2 polypeptide to a second antibody comprising a CDR sequence of PDO5 #810 or #811.
- 2. The antibody of claim 1, wherein the antibody is conjugated to an effector component.
- 3. The antibody of claim 2, wherein the effector component is a fluorescent label.
- 4. The antibody of claim 2, wherein the effector component is a radioisotope or a cytotoxic chemical.
- 5. The antibody of claim 4, wherein the cytotoxic chemical is auristatin.
- 6. The antibody of claim 1, wherein the antibody is an antibody fragment.
- 7. The antibody of claim 1, wherein the antibody is humanized.
- 8. The antibody of claim 1, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7, 8, 9 and 10.
- 9. The antibody of claim 1, wherein the SLC15A2 polypeptide is on a cancer or fibrosis cell.
- 10. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 1.
- 11. The pharmaceutical composition of claim 10, wherein the antibody is conjugated to an effector component.
- 12. The pharmaceutical composition of claim 11, wherein the effector component is a fluorescent label.
- 13. The pharmaceutical composition of claim 11, wherein the effector component is a radioisotope or a cytotoxic chemical.
- 14. The pharmaceutical composition of claim 13, wherein the cytotoxic chemical is auristatin.
- 15. The pharmaceutical composition of claim 10, wherein the antibody is humanized.
- 16. The pharmaceutical composition of claim 10, wherein the antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 7, 8, 9 and 10.
- 17. A method of detecting a cancer or fibrosis cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody of claim 1.
- 18. The method of claim 17, wherein the cancer or fibrosis cell is selected from the group consisting of an ovarian, uterine, prostate, lung, glioblastoma, cervical, or fibrosis-associated cell.
- 19. The method of claim 17, wherein the antibody is conjugated to a fluorescent label.
- 20. A method of inhibiting proliferation of an ovarian, uterine, prostate, lung, glioblastoma, cervical, or fibrosis-associated cell, the method comprising the step of contacting the cell with an antibody of claim 1.
- 21. The method of claim 20, wherein the antibody is an antibody fragment.
- 22. The method of claim 20, wherein the ovarian, uterine, prostate, lung, brain, cervical, or fibrosis cell is in a patient.
- 23. The method of claim 22, wherein the patient is a primate.
- 24. The method of claim 22, wherein the patient is undergoing a therapeutic regimen to treat metastatic ovarian cancer, uterine cancer, prostate cancer, lung cancer, or cervical cancer.
- 25. The method of claim 22, wherein the patient is suspected of having metastatic ovarian cancer, uterine cancer, prostate cancer, lung cancer, or cervical cancer.
- 26. An antibody comprising an amino acid sequence selected from the group of CDR sequences in SEQ ID NO: 7-10.
- 27. The antibody of claim 26, wherein the antibody is conjugated to an effector component.
- 28. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and the antibody of claim 26.
- 29. A method of detecting a cancer or fibrosis cell in a biological sample from a patient, the method comprising contacting the biological sample with an antibody of claim 26.
- 30. A method of inhibiting proliferation of an ovarian, prostate, lung, or cervical cancer or fibrosis-associated cell, the method comprising the step of contacting the cell with an antibody of claim 26.
CROSS-REFERENCES TO RELATED APPLICATIONS
[0001] This application claims priority from U.S. Provisional Application No. 60/451,294 filed Feb. 28, 2003, which is hereby incorporated by reference herein in its entirety.
[0002] This application also is related to U.S. Ser. No. 10/245,882 filed Sep. 17, 2002; and U.S. Ser. No. 10/295,027 filed Nov. 13, 2002; each of which is hereby incorporated by reference in its entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60451294 |
Feb 2003 |
US |